Definium's Phase 3 data for Spravato challenger Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 22 June, 2026

sponsored by Recruit NYC’s Top Biotech Talent at Biotech XYZ's Inaugural Career Fair Biotech XYZ's Inaugural Career Fair offers a unique opportunity to connect with a targeted biotech talent pool from across NYC's life sciences community. Recruit for internship and full-time roles, access candidate resume books, increase brand visibility, and engage directly with future biotech leaders through employer booths and industry speaking opportunities. Complete Interest Form

SPOTLIGHT No investors. A 50/50 split everyone warned us against. How Endpoints survived its first decade — and ended up at the FT

news AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates Sanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reins Definium reports Phase 3 hit for LSD drug in severe form of depression Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues Bionyra's $165M launch: A Sanofi alum, I&I candidates from China, one big catch-up Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration US government launches probe into Germany's plan to pay less for drugs  FDA vaccine advisors back Moderna’s flu vaccine, bucking past FDA leadership

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT

PHARMA Exclusive: Treasury is assessing options to screen investments in China biotech IRA's $2,000 out-of-pocket cap helped Medicare patients access expensive drugs, study finds Peer Review Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs News Briefing Pfizer CFO to depart; GSK wins approval for UTI drug

Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.

in case you missed it 1. Biogen makes up to $1B deal for secretive anti-inflammatory biotech 2. Kardigan raises $400M in IPO to back three clinical-stage cardio drugs 3. Innoviva revives Lyndra's long-acting oral drug platform, with Langer and Woodcock as advisors 4. RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea 5. Novocure’s electric fields therapy fails key glioblastoma study 6.